v3.25.1

Deferred income | 12 Months Ended
--- | ---
Dec. 31, 2024
Deferred income |
Deferred income | 27. Deferred income The movement in the non-current and current deferred income is detailed in the table below. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Gilead collaboration agreement for filgotinib |  | Gilead collaboration agreement for drug discovery platform (1) |  | Other deferred income |  | Total
​ | ​ | (Euro, in thousands)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​
On January 1, 2023 | ​ | € | 456,352 | ​ | € | 1,529,405 | ​ | € | 3,474 | ​ | ​ | 1,989,230
Of which current portion: | ​ | ​ | 133,470 | ​ | ​ | 230,022 | ​ | ​ | 2,139 | ​ | ​ | 365,631
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reclassification to liabilities directly associated with assets in disposal group classified as held for sale | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (60) | ​ | ​ | (60)
Significant financing component (2) | ​ | ​ | (645) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (645)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue recognition of upfront | ​ | ​ | (361,412) | ​ | ​ | (230,242) | ​ | ​ | ​ | ​ | ​ | (591,654)
Revenue recognition of milestones | ​ | ​ | (68,027) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (68,027)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other movements | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,382) | ​ | ​ | (1,382)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
On December 31, 2023 | ​ | € | 26,268 | ​ | € | 1,299,163 | ​ | € | 2,032 | ​ | € | 1,327,463
Of which current portion: | ​ | ​ | 25,054 | ​ | ​ | 230,070 | ​ | ​ | 1,146 | ​ | ​ | 256,270
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Significant financing component (2) | ​ | ​ | (227) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (227)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue recognition of upfront | ​ | ​ | (21,952) | ​ | ​ | (230,182) | ​ | ​ | ​ | ​ | ​ | (252,134)
Revenue recognition of milestones | ​ | ​ | (4,089) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (4,089)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other movements | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 339 | ​ | ​ | 339
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
On December 31, 2024 | ​ | € | — | ​ | € | 1,068,981 | ​ | € | 2,371 | ​ | € | 1,071,352
Of which current portion: | ​ | ​ | — | ​ | ​ | 230,105 | ​ | ​ | 2,371 | ​ | ​ | 232,476
(1) | The upfront received and the outstanding balance comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.
(2) | With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of money on the estimated recognition period
We refer to note 2 for a detail of the allocation of the transaction price of our collaboration with Gilead and to note 5 and note 7 for a description of our revenue recognition.

X
- Definition Deferred income [abstract] + References No definition available. + Details
Name: | glpg_DeferredIncomeAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of deferred income. [Refer: Deferred income including contract liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfDeferredIncomeExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration